TY -的T1 -一个新的字母慢性阻塞性肺病治疗:“E” stands for España JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01970-2016 VL - 49 IS - 1 SP - 1601970 AU - Young, Robert P. AU - Hopkins, Raewyn J. Y1 - 2017/01/01 UR - //www.qdcxjkg.com/content/49/1/1601970.abstract N2 - We read with interest the editorial by Kerwin [1] on the management of chronic obstructive pulmonary disease (COPD). This editorial follows the publication of the AFFIRM trial showing the superior bronchodilating effects of a long-acting muscarinic antagonist (LAMA)/long-acting β-agonist (LABA) combination over an inhaled corticosteroid (ICS)/LABA combination in a head-to-head trial, although symptom-based outcomes were not different [2]. These findings replicate those of the FLAME trial showing non-inferiority between a LAMA/LABA over an ICS/LABA combination, although reductions in exacerbations were greater in the former [3]. We would like to endorse the view of Kerwin [1] and Vogelmeier et al. [4] that it is a good time to “refine the paradigmatic GOLD classification”.An alternative schema to the 2011 GOLD A-to-D strategy, where the “E” category represents patients with ACOS only http://ow.ly/BGiN3069GKD ER -